Ellevest Inc’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Ellevest Inc’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-59	Closed	-$6.33K	–	1822
2023 Q1	$6.33K	Buy	59 +47	+392%	+$5.41K	﹤0.01%	1153
2022 Q4	$1.32K	Buy	12 +4	+50%	+$259	﹤0.01%	1458
2022 Q3	$0	Sell	8 -4	-33%	-$183	﹤0.01%	1954
2022 Q2	$0	Buy	+12	New	+$348	﹤0.01%	1793

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Ellevest Inc's RXDX Position: Q2 2023 in Review

Ellevest Inc sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 59 shares — an estimated $6.33K sold.

Ellevest Inc first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $6.33K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Ellevest Inc reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 59 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $6.33K.
Ellevest Inc first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Ellevest Inc's Prometheus Biosciences, Inc. Common Stock position peaked at $6.33K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.